Chevy, I see that as the most interesting part of the news release. I believe it means because Affitech gets exclusivity for the USSR using the future generation of treatments (and the risks that go with it) they get the better chance at big revenues quicker than whoever ends up with the currently under test Bavituximab revenue stream. I believe this means the Russian company was impressed with the Georgia and India trials; enough so that they are putting up money for a deal with Affitech for what would be a better expected result from the fully humanized versions. I would bet that under the Russian and CIS systems drug testing life cycles leading to approval are a lot shorter than the US and Europe. I'll have to look into that.
In turn for Affitech getting the USSR countries and the higher probablity for quicker returns on ivestments they allowed PPHM to have more of the pie for the remaining part of the world (or some other unknown portion thereof) for the EXISTING discovered and collaborated drug platforms.
It also seems to me that this is the beginning of the end of the collaborations between Affitech and PPHM for co-developing any future drugs.
This is my quick off the cuff take on this and of course my opinion.
News 
Market Data 
Discover 
